EX-99.2 3 ea165579ex99-2_cryomass.htm INVESTOR PRESENTATION SEPTEMBER 8, 2022

Exhibit 99.2


Revolutionizing Harvesting & Refinement of Cannabis & High Value Plants OTCQX: CRYM INVESTOR PRESENTATION TECHNOLOGIES SEPTEMBER 2022



Harvesting & Refinement Done More Efficiently CryoMass Technologies Inc. designs, manufactures and commercializes cryo - mechanical systems and processes for the harvesting and refinement of hemp, cannabis, and other high - value plants. Harvesting is simplified by processing fresh whole plant straight from the field while eliminating the need for bucking, trimming, drying and milling. This significantly reduces processing time, labor and cost while substantially increasing preservation of value components. Our patented cryogenic trichome separation module enables processors to scale the production of solventless products to an industrial capacity that is not currently achievable with existing technology. The system’s efficiency and yield are unmatched by the competing processes, and at a fraction of the operational cost. 2 ABOUT US



3 WHO WE ARE Revolutionizing Harvesting & Refinement Of Cannabis & High Value Plants OUR VISION To revolutionize the harvesting & refinement of high value plants while using the smallest ecological footprint . OUR PURPOSE To enhance cultivators and processors operational efficiencies with innovative technology that will translate into increased profits while enabling them to provide consumers with higher quality products . OUR VALUES Eco - Sustainable & Socially Responsible Committed to Innovation Driven by Science/Backed by Data Empower Through Education



Hemp & Marijuana Are The Same Plant; Cannabis sativa All forms of cannabis, including marijuana and hemp, belong to a single species - cannabis sativa 4 HEMP VS. MARIJUANA HEMP A term often used in policy to describe any cannabis variety with less than 0.3% THC. Traditionally bred for CBD, fiber and seed MARIJUANA A vernacular term typically used to describe cannabis with higher levels of THC (over 10%). Traditionally bred for cannabinoids – most notably THC



1. FLOWER Often called buds, cannabis flowers vary in appearance depending on their sex and genetic traits. The colours range widely with the most common being green, orange, red and purple. The female flower, having the highest concentration of trichomes, is the part of the plant that is consumed to experience the effects attributed to cannabis. 5 PLANT ANATOMY 2. TRICHOMES Cannabis trichomes contain, in varying quantities, several cannabinoid compounds, predominantly tetrahydrocannabinol (THC) and cannabidiol (CBD). Trichomes appear as tiny crystals all over the plant. They are bigger and denser on the flowers than on the leaves. 3. LEAF The symbol of the cannabis and something of an icon, the leaf is easily recognizable by its fan shape, pronounced venation and serrated leaflets. Leaf colour can range from pale green to dark olive green. TERPENES Different strains of cannabis have different sets of terpenes, which are comparable to essential oils. It is mainly the terpenes that give cannabis plants their particular aromas and flavours. 1 2 3



STALKS Stalks consist of an inner woody hurd fibre, and an outer string - like bast fibre. Hurd can be used for hempcrete, insulation, construction materials, mulch, paper, plastics, particle board, energy and biofuels and many other applications. Bast uses include pulp and paper, biocomposites, textiles, rope, construction materials, and energy and biofuels. 6 CANNABIS: A PLANT OF MANY USES LEAVES Leaves harness energy from the sun for plants to survive. They may be used for energy and biofuels, nutraceuticals, tea, cosmetics, compost, and various agro - chemicals. SEEDS Seeds are produced in female flowers. They contain a high amount of protein and beneficial fats. Seeds are used for protein powder, vegetable oils, cosmetics including topicals and hair products, energy and biofuels, flour, animal feed, and many other applications.



Importance Of T richomes Glandular trichomes are small resin glands found mostly on the surface of female flowers. These chemical factories produce hundreds of compounds including cannabinoids and terpenes. Cannabinoids, including THC and CBD, are responsible for the medicinal and sometimes psychoactive effects of cannabis. Terpenes (and terpenoids) are largely responsible for the characteristic smell of cannabis as well as contributing to the medicinal effects. Cannabinoids and terpenes are found almost exclusively within the glandular trichomes and nowhere else on the plant. Not only are these compounds very sensitive to environmental factors such as oxygen, heat and light, the trichomes housing these compounds are very delicate and will readily fracture or detach when subjected to physical agitation. 7 WHY TRICHOMES?



T r aditional Harvesting & Processing Methods Incur Enormous Loss Of T richomes 8 CRYOMASS VS. CONVENTIONAL PROCESSING METHODS Conventional processing methods haven’t changed much since the 1960s, when the industry operated illegally out of someone’s backyard. The methods waste a third or more of the plant’s most desired elements – the trichomes. The trouble starts with the fragility of trichomes. They break off easily and are lost forever in the same way a Christmas tree loses its needles when handled and then are gone forever. With conventional handling and drying, every step shakes off more of them. All in all, roughly one - third of the trichomes are lost. When the plant is handled and trucked to a drying facility, the loss of trichomes accelerates. Then – midway through drying – the flower becomes extremely brittle and trichome loss becomes exponential , like the needles of a Christmas tree being forced through the front door at the end of the holiday season. By that point, the plant still needs to be handled and transported to the extraction facility. The biggest challenge in any plant processing is to capture all the valuable elements that are wrapped up inside the plant at the moment of harvest. There really was no way to accomplish this…until now.



What Have T richomes Been T r aditionally Used For? 9 USE OF TRICHOMES Hashish, also known as hash, is a cannabis concentrate product composed of compressed or purified preparations of stalked resin glands, called trichomes. Hash has a long history of usage in countries such as Morocco, Afghanistan, India, Iran, Israel, and Lebanon. The sticky resins glands of the fresh flowering female cannabis plant are collected. Traditionally this was, and still is, done in remote locations by pressing or rubbing the flowering plant between two hands and then forming the sticky resins into a small ball of hashish called charas. This method produces the highest amount of cannabinoids (THC content up to 60%) without chemical solvents or distillation. Mechanical separation methods use physical action to remove the trichomes from the dried plant material, such as sieving through a screen by hand or in motorized tumblers. This technique is known as "drysifting". The resulting powder, referred to as "kief" or "drysift", is compressed with the aid of heat into blocks of hashish. Ice - water separation is another mechanical method of isolating trichomes .



How Were T richomes Collected Before CryoMass ? 10 CRYOMASS VS. CONVENTIONAL PROCESSING METHODS Traditional trichome separation methods are rudimentary at best. The cannabis flower is typically placed in a mesh bag, soaked in ice water and then agitated to separate the trichomes. The careful agitation is done by machine or by hand, using paddles. Trichomes may break away from supporting flower and leaves when plant material becomes brittle at low temperatures. After plant material has been agitated in an icy slush, separated trichomes are often dense enough to sink to the bottom of the ice - water mixture following agitation, while lighter pieces of leaves, stems and other plant particles tend to float. The water is then left to settle and the trichomes at bottom of the tank are isolated using filtration bags with various - sized screens. Manual Trichome Separation Traditional Ice Water Trichome Separation System



11 CRYOMASS VS. TRADITIONAL SYSTEMS CryoMass vs. T r aditional T richome Separation Systems When comparing the results of the patented CryoMass system to traditional ice water trichome separation systems, there is no comparison. Based on the processing of 25,000 lbs of biomass, here is a comparison of our trichome separation system versus nine leading traditional systems that do not and cannot utilize our patented cryogenic, solventless separation process. They use ice water instead. It is important to note that one of the key reasons the CryoMass system is so much more efficient from a process and cost - saving perspective is that it is, to the best of our knowledge, the only continuous - feed separation system while all others are batch - feed systems. Although the Company's initial focus is on the cannabis and hemp sector, there is tremendous potential to generate important revenue streams from processing other high - value, trichome - rich plants where similar cost savings and end - product improvements can be realized. CRYOMASS TRADITIONAL Biomass processed/hour (lbs.) Separation time in days (based on 12 - hour days) Expected average trichome yield (Ibs.) Operating expenses ($) 䘿 Traditional systems data was gathered from company websites and from conversations with company representatives . This is an average of the 9 leading traditional systems . 1300 60 1.6 66 8,000 1,750 2,816 33,533 41x FASTER 22x MORE 4.5x MORE 90% SAVINGS



12 OUR MACHINE Bringing Never Before Seen Efficiencies & Options To Cannabis & High Value Plant Operators INDUSTRIAL CAPACITY Process up to 1,300 lbs/600,000 grams of fresh biomass per hour per system. ELIMINATE DRYING & TRIMMING Process fresh whole plants straight from the field and reduce days of work & trichome loss. BIOMASS VERSATILITY Process wet or dry, fresh frozen, whole plant, cured flower, trim and everything in between. MOBILE OR FIXED UNITS Our system can be operated at the cultivation site or be permanently installed in a processing facility. GREEN PROCESS Minimal energy usage and no organic solvents. Minimal ecological footprint . VOLUME Reduce volume of product up to 80% relative to starting material, making storage and transportation less burdensome . OUTPUT Increase cannabinoid and terpene concentration up to 10x .



13 CRYOSIFT & WHAT IT MAKES SOLVENTLESS PRODUCTS CRYOSIFT IS TRICHOMES IN THEIR PUREST FORM • CryoSift can be used for making THC and CBD products for medicinal, wellness and recreational purposes . It can also be used for making CBD products for animals . • The quality of CryoSift is superior to sift obtained with traditional dry and water - based trichome separation methods. Cryogenic separation results in increased cannabinoid yields, higher terpene count for a greater retention of the most desirable compounds. • Though CryoSift can be consumed as is, it is the ideal input for manufacturing superior premium concentrates at scale, without the use of solvents (solventless) . • CryoSift can also be used as a high - quality feedstock for traditional solvent - based extraction methods (such ethanol, CO2 or hydrocarbon) to create extracts with different flavor, color and aroma profiles like live resin concentrates. We Call The Result Of Our Cryogenic Trichome Separation - CryoSift SOLVENT BASED PRODUCTS THC & CBD Live Rosin Concentrates & Vapes, Hash, Tinctures, Edibles, Gel Caps, Beverages, Pre - Rolls, Etc. CRYOSIFT THC & CBD Live Resin Concentrates & Vapes, Distillate, Tinctures, Edibles, Gel Caps, Beverages, Etc.



14 WHO CAN USE CRYOMASS? Industries That Can Use Our T echnolo g y We are also exploring the application of our process to a broad range of industries that handle high - value plants which could benefit from our precision capture , cryo - preservation and separation technology PHARMACEUTICAL Numerous compounds of medicinal interest grow in trichome - containing plant species including natural fungicides and antibiotics to name a few AGRICULTURE Cryo preservation and refinement of standard agricultural crops FOOD & BEVERAGE NUTRACEUTICALS Hops for beer and grapes for wine



Where it Began Early R&D Establishing Patents Patent Applications August 2015 March 2016 June 2016 May 2017 The concept of using cryogenic First separation of trichomes Matt Armstrong began writing Official patent applications with fluid to separate trichomes & from biomass using cryogenic the cryogenic separation patent the US patent office (USPTO), produce extracts without fluid was performed in Long with the intent to keep it as European patent office (EPO) & solvents was born in California Beach, California broad as possible many other countries Testing 1st Prototype US Patent Granted Dev 2nd Prototype CryoCann Acquired June 2020 December 2020 April 2021 June 2021 Began assembling and testing Approval & grant date of initial Began 2 nd generation CryoCann CryoCann USA assets are of 1st generation CryoCann patent (valid until 2038) by system design with California acquired by CryoMass prototype The United States Patent and Trademark Office (USPTO) based manufacturer Technologies Inc China Patent Granted Further Testing CAN Patent Granted First Unit Dispatched September 2021 December 2021 May 2022 September 2022 Granted patent (valid until Began testing of individual CryoMass receives Canadian Anticipated delivery of our 2038) from the Chinese components of the 2 nd patent (valid until 2039) and 1 st commercial unit at operating Intellectual Property Office generation prototype begins real - time trials of a full - scale, user - ready model of its patented cryogenic trichome separation unit partner facility in Monterey, California. 15 CRYOMASS MILESTONES



16 MARKET DATA Global cannabis product sales will reach US$35 billion in 2022, and are projected to reach US$61 billion by 2026 (1) 1 st commercial unit at operating partner facility will cover 60% of California cultivation licences CALIFORNIA Legal Cannabis product sales in California totalled US$431.3 million in June 2022. Suggesting an annual run - rate of US$5.175 billion (6) 1. 2. 3. 4. 5. 6. https://bdsa.com/wp - content/uploads/2022/03/Cannabis - Market - Forecast - Spring - 2022 - Update.pdf https://prohibitionpartners.com/2022/08/04/the - north - american - cannabis - report - 3rd - edition - key - insights/ https:// www.canada.ca/en/health - canada/services/drugs - medication/cannabis/research - data/market/licensed - area.html https:// www.hempbenchmarks.com/interactive/total - us - hemp - acres - permitted - planted - harvested/ https:// www.canada.ca/en/health - canada/services/drugs - medication/cannabis/producing - selling - hemp/about - hemp - canada - hemp - industry/statistics - reports - fact - sheets - hemp.html https:// www.newcannabisventures.com/june - cannabis - sales - decrease - slightly - from - may - to - 1 - 65 - billion/ Product sales projected to grow from US$18.5 billion in 2022 to US$58.8 billion in 2026 (2) USA CANNABIS In 2021, 30,000 acres of hemp were harvested for a total of ~30 million pounds of biomass (4) USA HEMP Product sales of US$4 billion in 2021 projected to be US$7.6 billion in 2026 (2) 2,196 acres of licensed cultivation in 2021 (3) CANADA CANNABIS 1 , 269 industrial hemp licenses in 2020 with 54 , 963 acres of cultivation ( 5 ) CANADA HEMP Initial Market Focus Is North America



17 OUR TEAM Leadership T eam CryoMass Technologies is led by an extremely experienced and talented group of individuals who offer perspectives based on their diverse backgrounds and skill sets. From our corporate officers to our board of directors, the company is well suited for future growth. Christian Noël Blair Mullin Patricia Kovacevic Matt Armstrong Aaron Godin Mike Stringile Steve Cimini CEO CFO General Counsel & Head of External A f fairs Director of Innovation Director of Applied Science Director of Int’l Sales Director of US Sales



18 OUR BOARD Dr. Delon Human, Chairman Dr. Delon Human, M.B.Ch.B., M.Prax.Med, MFGP, DCH, MBA is a recognized global health leader, published author, lecturer and healthcare consultant. Board Of Directors Mario Gobbo, Director Mario Gobbo has 35 years of banking and corporate finance experience in healthcare and energy. Mark Radke, Director Mark Radke is a lawyer with a distinguished career in the area of financial services, specializing in federal securities regulation. Christian Noël, CEO & Director Christian Noël is a trusted investor and business strategist, who has held senior positions in financial and investment organizations in Montreal, Canada, for the last 21 years. Simon Langelier, Director Simon Langelier has extensive experience in the international tobacco industry and is currently a director of Imperial Brands PLC, after a 30 - year career with Philip Morris International.



Get in T ouch The common stock of CryoMass Technologies Inc. trades on the OTCQX market under the symbol CRYM . For further information, please contact us using a method below: investors@cryomass.com +1 (833) 256 - 2382 or +1 (303) 222 - 8092 WE WELCOME YOUR INQUIRIES



Disclaimer This documenta/on is a presenta/on (the “Presenta/on”) of general background informa/on about Cryomass Technologies Inc. inc. (“Cryomass Technologies Inc.” or “the Company”). It is informa/on in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or poten/al investors and does not take into account the investment objec/ves, financial situa/on or needs of any par/cular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate. This Presenta/on does not cons/tute or form part of any offer for sale or solicita/on of any offer to buy or subscribe for securi/es nor shall it or any part of it form the basis of or be relied on in connec/on with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this Presenta/on who are considering acquiring securi/es of Cryomass Technologies Inc.are reminded that any such purchase or subscrip/on must not be made on the basis of the informa/on contained in this Presenta/on but are referred to the en/re body of publicly disclosed informa/on regarding Cryomass Technologies Inc.. The informa/on contained in this Presenta/on is derived solely from management of Cryomass Technologies Inc.and otherwise publicly available informa/on concerning Cryomass Technologies Inc.and does not purport to be all - inclusive or to contain all the informa/on that an investor may desire to have in evalua/ng whether or not to make an investment in Cryomass Technologies Inc.. The informa/on has not been independently verified and is subject to material upda/ng, revision and further amendment, and is qualified en/rely by reference to Cryomass Technologies Inc.’s publicly disclosed informa/on. No representa/on or warranty, express or implied, is made or given by or on behalf of Cryomass Technologies Inc.or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the informa/on or opinions contained in this Presenta/on and no responsibility or liability is accepted by any person for such informa/on or opinions. Cryomass Technologies Inc.does not undertake or agree to update this Presenta/on or to correct any inaccuracies in, or omissions from, this Presenta/on that may become apparent. No person has been authorized to give any informa/on or make any representa/ons other than those contained in this Presenta/on and, if given and/or made, such informa/on or representa/ons must not be relied upon as having been so authorized. The informa/on and opinions contained in this Presenta/on are provided as at the date of this Presenta/on. The contents of this Presenta/on are not to be construed as legal, financial or tax advice. Each prospec/ve investor should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice. Certain statements in this Presenta/on may cons/tute forward - looking informa/on, including future - oriented financial informa/on and financial outlooks, within the meaning of applicable securi/es laws. Forward looking informa/on may relate to Cryomass Technologies Inc.’s future outlook and an/cipated events or results and may include statements regarding Cryomass Technologies Inc.’s financial results, future financial posi/on, expected growth of cash flows, business strategy, budgets, projected costs, projected capital expenditures, taxes, plans, objec/ves, poten/al synergies, industry trends and growth opportuni/es. OSen but not always, forward - looking informa/on can be iden/fied by the use of words such as “an/cipate”, “believe”, “expect”, “project”, “es/mate”, “likely”, “intend”, “should”, “could”, “may”, “might”, “target”, “plan” and other similar expressions or varia/ons (including nega/ve varia/ons) of such words and phrases. Forward - looking informa/on contained in this Presenta/on is based on certain assump/ons regarding expected growth, results of opera/ons, performance, industry trends and growth opportuni/es. While management considers these assump/ons to be reasonable, based on informa/on available, they may prove to be incorrect. Forward - looking statements involve known and unknown risks, uncertain/es and other factors which may cause the actual results, performance or achievements of Cryomass Technologies Inc.to be materially different from any future results, performance or achievements expressed or implied by the forward - looking statements. These risks, uncertain/es and other factors include, but are not limited to risks associated with general economic condi/ons; adverse industry events; marke/ng costs; loss of markets; future legisla/ve and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory maVers; the ability of Cryomass Technologies Inc.to implement its business strategies; compe//on; crop failure; currency and interest rate fluctua/ons, and the other risks. The foregoing factors are not intended to be exhaus/ve. Although Cryomass Technologies Inc.has aVempted to iden/fy important factors that could cause actual ac/ons, events or results to differ materially from those described in forward - looking statements, there may be other factors that cause ac/ons, events or results to differ from those an/cipated, es/mated or intended. Forward - looking statements contained herein are made as of the date hereof and CryoMass Technologies Inc.and its directors, officers and employees disclaim any obliga/on to update any forward - looking statements, whether as a result of new informa/on, future events or results or otherwise. There can be no assurance that forward - looking statements will prove to be accurate, as actual results and future events could differ materially from those an/cipated in such statements. Accordingly, you should not place undue reliance on forward - looking statements due to the inherent uncertainty therein. All forward - looking informa/on is expressly qualified in its en/rety by this cau/onary statement. Forward - looking informa/on and other informa/on contained herein concerning management’s general expecta/ons concerning the medical marijuana industry are based on es/mates prepared by management using data from publicly available industry sources as well as from market research and industry analysis and on assump/ons based on data and knowledge of this industry which management believes to be reasonable. However, this data is inherently imprecise, although generally indica/ve of rela/ve market posi/ons, market shares and performance characteris/cs. While management is not aware of any misstatements regarding any industry data presented herein, industry data is subject to change based on various factors. This Presenta/on may not be reproduced, further distributed or published in whole or in part by any other person. Neither this Presenta/on nor any copy of it may be taken or transmiVed into or distributed in any other jurisdic/on which prohibits the same except in compliance with applicable laws. Any failure to comply with this restric/on may cons/tute a viola/on of applicable securi/es law. Recipients are required to inform themselves of, and comply with, all such restric/ons or prohibi/ons and Cryomass Technologies Inc.does not accept liability to any person in rela/on thereto.